NEW YORK (GenomeWeb News) – Coriell Institute for Medical Research today said that it is collaborating with the National Institutes of Health to make a new line of stem cells available to researchers.
The lines of induced pluripotent stem cells are available through the National Institutes of General Medical Sciences' Human Genetic Cell Repository at Coriell. The stem cells, made from skin or blood cells, were derived from individuals with Huntington's disease, juvenile onset diabetes, muscular dystrophy, spinal muscular atrophy, and severe combined immunodeficiency.
"The promise of stem cell research lies in its application in understanding the progression of human disease, to better target therapies to optimize our health outcomes, and to ultimately use stem cells therapeutically to cure disease and reverse injury," Coriell President and CEO Michael Christman said in a statement.
The NIGMS Human Genetic Cell Repository has been managed by Camden, NJ-based Coriell since 1972 and currently contains more than 10,500 cell lines, said Coriell.